EC Number   |
Application |
Reference |
|---|
    5.1.1.18 | drug development |
serine racemase inhibitors are therapeutic candidates for the treatment of neurodegenerative disorders and epileptic states |
747283 |
| 5.1.1.18 | drug development |
serine racemase inhibitors might be useful in treatment of neurodegenrative diseases |
703286 |
| 5.1.1.18 | drug development |
serine racemase is a promising target for the development of specific inhibitors in the treatment of disorders related to NMDAR dysfunction. Analysis of the molecular basis for rational drug design using the X-ray crystal structures of human and rat serine racemase |
704657 |
| 5.1.1.18 | drug development |
the enzyme and enzyme mutants may serve as targets for future docking studies and drug design |
747090 |
| 5.1.1.18 | medicine |
elevated levels of enzyme mRNA in Alzheimer´s disease hippocampus |
662682 |
| 5.1.1.18 | medicine |
serine racemase is the major enzyme for D-serine production in the brain, D-serine is the predominant endogenous coagonist of the NMDA receptor in the forebrain, and D-serine may be involved in controlling the extent of NMDA receptor-mediated neurotoxic insults observed in disorders including Alzheimer's disease. |
693753 |
| 5.1.1.18 | medicine |
targeted disruption of serine racemase results in profoundly altered glutamatergic neurotransmission and subtle but significant behavioral abnormailites that reflect hyperactivity and impaired spatial memory, and that are consistent with elevated anxiety |
694278 |
| 5.1.1.18 | pharmacology |
because D-serine affects NMDAR signaling throughout the brain, serine racemase is a promising target for the treatment of disorders related to NMDAR dysfunction |
704657 |
